Wells Fargo sets USD 1,356 target for argenx stock

Published on 10/15/2026 at 11:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wells Fargo set a USD 1,356.00 target on October 14, 2026. argenx stock costs EUR 747.40 on October 15 before October 22 results.

Analyst view and upcoming results

Wells Fargo set a USD 1,356.00 target on October 14, 2026.
Second-quarter revenue reached USD 1.54 billion, while adjusted earnings per share came to USD 7.32.
argenx stock was trading at EUR 747.40 at 11:03 a.m. CEST at Lang & Schwarz on October 15, 2026.
Third-quarter results are scheduled for October 22, 2026.

Pop-Art-Comic im Lichtenstein-Stil: Stilisierte Antikörper kämpfen gegen Viren, knalliges Magenta Gelb Cyan und Schwarz, Halbtonpunkte, dynamische Diagonale, keine Texte — Argenx NL0010832176 Immunsystem als Pop-Art-Comic mit Antikörpern die Erreger dynamisch bekämpfen illustriert, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) stock was trading at EUR 747.40 at Lang & Schwarz on October 15, 2026, at 11:03 a.m. CEST. Markets Insider reported on October 14, 2026, that Wells Fargo analyst Derek Archila maintained a Buy rating and set a USD 1,356.00 price target.

Why the target matters

The Wells Fargo target puts the latest analyst view alongside a sharply stronger second quarter. According to MarketBeat, argenx reported USD 1.54 billion in second-quarter revenue versus USD 1.45 billion expected, while earnings per share reached USD 7.32 against a USD 5.86 consensus estimate.

That operating comparison is important because the pipeline also carries clinical risk. The company had USD 3.58 billion in cash and cash equivalents as of June 30, 2026, while operating cash flow for the second quarter was USD 325.5 million.

Three dated developments

On October 8, 2026, argenx reported positive Phase 2 FB102 celiac-disease data from 126 adults, according to RTTNews. On the same date, argenx announced the discontinuation of the Phase 3 UNITY study after an interim analysis found that it was unable to meet its primary endpoint. On October 15, 2026, the company announced a third-quarter results webcast for October 22, 2026.

What date comes next

The next reporting date is October 22, 2026, when argenx plans to discuss third-quarter financial results and provide a business update at 2:30 p.m. CET, according to MarketScreener.

Stock price and company scale

The euro quotation gives investors in Germany a direct trading reference, while the company remains valued at USD 51.5 billion on the primary Nasdaq market as of October 14, 2026. The same market context places the 52-week range at USD 661.85 to USD 1,072.75, leaving the current U.S. quotation below its yearly high.

argenx develops immunology medicines for autoimmune diseases, with VYVGART and VYVGART Hytrulo among its approved therapies. The balance between commercial growth, cash resources and clinical execution will shape the next update.

argenx was trading at EUR 747.40 at Lang & Schwarz on October 15, 2026, at 11:03 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.